Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
This study is ongoing, but not recruiting participants.
Study NCT00072046 Information provided by National Cancer Institute (NCI)
First Received: November 4, 2003 Last Updated: June 19, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Cancer
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
More general conditions related to this trial
Adenocarcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
bevacizumab
recombinant interferon alfa
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Alfa-2b
Interferon Type I, Recombinant
Interferon-alpha
Interferons
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Cancer and Leukemia Group B
National Cancer Institute (NCI)
NCIC Clinical Trials Group
Eastern Cooperative Oncology Group
Back to top of Main Content
